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Summary
Background Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine 
kinase AKT. The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-
free survival in patients with aromatase inhibitor-resistant advanced breast cancer.
Methods In this randomised, double-blind, placebo-controlled, phase 2 trial, postmenopausal women aged at least 
18 years with an Eastern Cooperative Oncology Group performance status of 0–2 and oestrogen receptor-positive, 
HER2-negative, metastatic or locally advanced inoperable breast cancer who had relapsed or progressed on an 
aromatase inhibitor were recruited from 19 hospitals in the UK. Enrolled participants were randomly assigned (1:1) to 
receive intramuscular fulvestrant 500 mg (day 1) every 28 days (plus a loading dose on day 15 of cycle 1) with either 
capivasertib 400 mg or matching placebo, orally twice daily on an intermittent weekly schedule of 4 days on and 
3 days off (starting on cycle 1 day 15) until disease progression, unacceptable toxicity, loss to follow-up, or withdrawal 
of consent. Treatment allocation was done using an interactive web-response system using a minimisation method 
(with a 20% random element) and the following minimisation factors: measurable or non-measurable disease, 
primary or secondary aromatase inhibitor resistance, PIK3CA status, and PTEN status. The primary endpoint was 
progression-free survival with a one-sided alpha of 0·20. Analyses were done by intention to treat. Recruitment is 
complete, and the trial is in follow-up. This trial is registered with ClinicalTrials.gov, number NCT01992952.
Findings Between March 16, 2015, and March 6, 2018, 183 patients were screened for eligibility, of whom 140 (76%) 
were eligible and were randomly assigned to receive fulvestrant plus capivasertib (n=69) or fulvestrant plus placebo 
(n=71). Median follow-up for progression-free survival was 4·9 months (IQR 1·6–11·6). At the time of primary 
analysis for progression-free survival (Jan 30, 2019), 112 progression-free survival events had occurred, 49 (71%) in 
69 patients in the capivasertib group compared with 63 (89%) of 71 in the placebo group. Median progression-free 
survival was 10·3 months (95% CI 5·0–13·2) in the capivasertib group versus 4·8 months (3·1–7·7) in the placebo 
group, giving an unadjusted hazard ratio (HR) of 0·58 (95% CI 0·39–0·84) in favour of the capivasertib group 
(two-sided p=0·0044; one-sided log rank test p=0·0018). The most common grade 3–4 adverse events were 
hypertension (22 [32%] of 69 patients in the capivasertib group vs 17 [24%] of 71 in the placebo group), diarrhoea 
(ten [14%] vs three [4%]), rash (14 [20%] vs 0), infection (four [6%] vs two [3%]), and fatigue (one [1%] vs three [4%]). 
Serious adverse reactions occurred only in the capivasertib group, and were acute kidney injury (two), diarrhoea (three), 
rash (two), hyperglycaemia (one), loss of consciousness (one), sepsis (one), and vomiting (one). One death, due to 
atypical pulmonary infection, was assessed as possibly related to capivasertib treatment. One further death in the 
capivasertib group had an unknown cause; all remaining deaths in both groups (19 in the capivasertib group and 
31 in the placebo group) were disease related.
Interpretation Progression-free survival was significantly longer in participants who received capivasertib than in 
those who received placebo. The combination of capivasertib and fulvestrant warrants further investigation in phase 3 
trials.
Funding AstraZeneca and Cancer Research UK.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Breast cancer is the most common cancer diagnosis 
worldwide, and the oestrogen receptor is expressed 
in most tumours. Endocrine therapies targeting the 
oestrogen receptor are an integral component of treat­
ment for oestrogen receptor­positive breast cancer, but 
resistance develops in almost all patients with advanced 
disease. Several resistance mechanisms have been 
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identified, including alteration of the PI3K/AKT pathway. 
This pathway is altered in more than 50% of oestrogen 
receptor­positive advanced breast cancers, most frequently 
through somatic hotspot mutation in exons 9 and 20 of 
PIK3CA, encoding the p110α isoform of PI3K.1–4 Less 
frequently, pathway alteration is induced by loss of 
function mutation or deletion of the negative regulator 
PTEN or activating mutations in AKT1. PI3K pathway 
alteration is associated with endocrine therapy resistance 
through ligand inde pendent activation of the oestrogen 
receptor.5,6 Conversely, preclinical data show compensatory 
increases in ligand­dependent oestrogen receptor 
transcription following PI3K pathway inhibition.7–9 A 
rationale therefore exists for simultaneously targeting 
both the oestrogen receptor and PI3K pathways.
Several clinical trials have reported improved 
progression­free survival with inhibitors of the PI3K 
pathway in combination with endocrine therapies. Distal 
inhibition with the mTORC1 inhibitor everolimus 
improved progression­free survival in combination with 
the aromatase inhibitor exemestane irrespective of the 
alteration status of the PI3K pathway, albeit at the cost 
of additional toxicity.3,10 By contrast, proximal pathway 
inhibition with the PI3Kα­subunit specific inhibitor 
alpelisib significantly enhanced the efficacy of fulvestrant, 
but only in tumours harbouring PIK3CA hotspot 
mutations.11 This finding has led to selected approval for 
alpelisib, in combination with fulvestrant, in this specific 
subgroup of patients with oestrogen receptor­positive 
advanced breast cancer. An unmet need therefore 
remains for patients whose tumours do not carry 
PIK3CA hotspot mutations.
Capivasertib (AZD5363) is a potent and selective 
inhibitor of the three AKT isoforms. Preclinical data 
show synergistic activity with fulvestrant in both 
endocrine­sensitive and endocrine­resistant models of 
oestrogen receptor­positive breast cancer.12 Preliminary 
clinical activity was seen with capivasertib monotherapy 
in heavily pre­treated patients with AKT1­mutant solid 
cancers, including oestrogen receptor­positive breast 
cancer, but very low single­agent activity in patients with 
PIK3CA­mutant breast and gynaeco logical cancers.13,14 In 
the phase 2 BEECH trial, capivasertib did not enhance 
the efficacy of paclitaxel in oestrogen receptor­positive 
advanced breast cancer, although endocrine therapy was 
not permitted in this study as is standard practice.15 In a 
phase 1b study, we determined the capivasertib dose to 
be used in combination with fulvestrant was 400 mg 
twice daily for 4 days then 3 days off in a weekly schedule.16
In the phase 2 FAKTION trial, we assessed the efficacy 
and safety of capivasertib plus fulvestrant in post­
menopausal women with aromatase inhibitor­resistant, 
oestrogen receptor­positive, HER2­negative advanced 
or metastatic breast cancer. Furthermore, the relative 
efficacy of the treatment combination in participants with 
and without alteration of the PI3K pathway was assessed.
Research in context
Evidence before this study
We searched PubMed between Jan 1, 2009, and July 31, 2019, 
to identify publications directly relevant to the FAKTION clinical 
setting using the search terms “AKT” or “PI3K” or “mTOR” and 
“oestrogen receptor” and “breast cancer” and “metastatic” and 
“inhibitor” or “inhibition”. We also searched PubMed for 
publications in the same period using the terms “capivasertib” 
or “AZD5363”. We did not use any language restrictions in our 
search. We found no reports of randomised trials investigating 
the inhibition of AKT in combination with endocrine therapies 
in oestrogen receptor-positive, HER2-negative breast cancer. 
The only other randomised phase 2 study of AKT inhibition in 
patients with oestrogen receptor-positive, HER2-negative 
breast cancer showed no advantage of addition of 
capivasertib to paclitaxel chemotherapy. Five randomised, 
placebo-controlled trials tested the addition of PI3K or mTOR 
inhibitors to endocrine therapies. These studies have shown 
pan-PI3K and beta-sparing inhibitors to have an unfavourable 
toxicity profile and low clinical activity, and they are no longer 
in development for this indication. The alpha-specific PI3K 
inhibitor, alpelisib has activity in combination with fulvestrant, 
but only in PIK3CA-mutant tumours and toxicity remains 
problematic. mTOR inhibition with everolimus has shown 
activity, again at the cost of substantial toxicity, but the effect is 
agnostic to perturbation of the PI3K pathway.
Added value of this study
To our knowledge, this study is the first randomised trial to 
report on the addition of an AKT inhibitor to endocrine 
therapy in oestrogen receptor-positive metastatic breast 
cancer after previous aromatase inhibitor therapy. The results 
showed an improvement in progression-free survival and 
response rate with addition of capivasertib to endocrine 
therapy, suggesting synergy, in contrast to the poor efficacy 
in combination with chemotherapy. Adverse events were 
common, but manageable with dose reduction, and did not 
seem to compromise efficacy.
Implications of all the available evidence
Several approaches to targeting the PI3K/AKT/mTOR pathway 
have been shown to be effective in metastatic oestrogen 
receptor-positive, HER2-negative breast cancer in 
combination with endocrine therapy. AKT and mTOR 
inhibition seems to be active in a broader population of 
patients than PI3K inhibitors. The intermittent scheduling of 
capivasertib in this study contrasts with the continuous 
treatment with PI3K and mTOR inhibitors in the majority of 
previous publications, potentially resulting in improved 
tolerability. The FAKTION data support further investigation 
of AKT inhibition with capivasertib in combination with 
fulvestrant in a phase 3 trial.
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Methods
Study design and participants
We did an investigator­initiated, multicentre, randomised, 
double­blind, placebo­controlled, biomarker­adaptive, 
phase 2 trial, in which patients were enrolled from 
19 hospitals in the UK (appendix p 20). Eligible patients 
were post menopausal women aged at least 18 years with 
locally confirmed oestrogen receptor­positive, HER2­
negative metastatic or locally advanced inoperable breast 
cancer and Eastern Cooperative Oncology Group 
performance status of 0–2. Oestrogen receptor­positive 
was defined as at least 10% of tumour cells staining 
positive for oestrogen receptor in the primary tumour or a 
metastatic sample. If no percentage score was available, a 
Quick (Allred) score of at least 4 out of 8 was considered 
oestrogen receptor­positive. Participants’ cancers were 
required to have relapsed on or within 12 months of 
adjuvant aromatase inhibitor therapy or have progressed 
on an aromatase inhibitor in the metastatic setting 
(although this did not need to be the most recent therapy). 
Participants were categorised as having either primary or 
secondary resistance to aromatase inhibitor therapy. 
Primary resistance was defined as either disease relapse 
during or within 6 months of completing aromatase 
inhibitor treatment in the adjuvant setting, or disease 
progression within 6 months of starting aromatase 
inhibitor treatment and no response to aromatase 
inhibitor treatment in the metastatic setting. Secondary 
resistance was defined as disease relapse more than 
6 months after completion of aromatase inhibitor 
treatment in the adjuvant setting, or disease progression 
following achievement of clinical benefit with aromatase 
inhibitor treatment in the meta static setting. Radiological 
or objective clinical evidence of relapse or progression on 
or after the last systemic therapy before enrolment was 
required, but not further defined in the protocol. 
Participants could have measurable or non­measurable 
disease according to Response Evaluation Criteria in Solid 
Tumours (RECIST) version 1.1. Up to three previous lines 
of endocrine therapy and one line of cytotoxic chemo­
therapy were permitted for metastatic breast cancer. 
Participants were required to have a life expectancy of at 
least 12 weeks and adequate organ function (absolute 
neutrophil count ≥1·0 × 10⁹ per L; platelet count ≥100 × 10⁹ 
per L; haemoglobin ≥9 g/dL; international normalised 
ratio ≤1·5; potassium, calcium [corrected for serum 
albumin], and magnesium within normal limits for the 
institution; serum creatinine ≤1·5 times the upper limit of 
normal; alanine aminotransferase and aspartate amino­
transferase ≤1·5 times the upper limit of normal [or 
<3·0 times if liver metastases]; total bilirubin ≤1·5 times 
the upper limit of normal; and fasting glucose 
<7·0 mmol/L). Key exclusion criteria included previous 
treatment with fulvestrant or inhibitors of the PI3K/AKT 
pathway, and clinically significant abnormalities of 
glucose meta bolism. Participants with well controlled 
type 2 diabetes with an Hba1c of less than 42 mmol/mol 
(<8%) and fasting blood glucose of less than 9·3 mmol/L 
could participate following a protocol amendment on 
June 11, 2015. A further protocol amendment on 
Feb 27, 2017, was implemented to allow women with 
previous malignancy, in remission for at least 5 years, and 
those with bilateral oophorectomy (to define menopause) 
to participate. Protocol deviations are outlined in the 
appendix (p 4), as are the full inclusion and exclusion 
criteria (appendix pp 21–116).
Written, informed consent was obtained from all 
participants before trial screening procedures and 
enrolment. The trial was approved by the North West—
Haydock Research Ethics Committee, Manchester, UK 
(reference number 13/NW/0842). The trial was done in 
accordance with the principles of Good Clinical Practice, 
the Declaration of Helsinki, and UK clinical trial 
regulations.
Randomisation and masking
Participants were randomly assigned (1:1) to receive 
fulvestrant plus capivasertib or fulvestrant plus placebo. 
Randomisation was done centrally, using minimisation 
with a 20% random element.17 Minimisation factors 
were measurable versus non­measurable disease, pri­
mary versus secondary resistance to a third­generation 
aromatase inhibitor, PIK3CA mutation status (mutated 
vs wild­type), and PTEN expression status (null vs 
detected in ≥1% of tumour cells at moderate or strong 
intensity or ≥10% of cells at weak intensity). An 
interactive web­response system based on blinded drug 
pack number was used for treatment allocation. 
Participants were assigned six­digit trial numbers and 
treatment groups and a confirmatory email including 
the participant’s trial number, initials, date of birth, and 
treatment kit numbers was sent to the investigator. 
Capivasertib tablets and matching placebo had identical 
packaging, labelling, appearance, and administration 
schedules. Investigators used the interactive web­
response system to receive new kit numbers for 
subsequent cycles. Participants, investigators, study site 
staff, and sponsor were masked to treatment assignment 
until database lock.
Procedures
Participant blood and tissue samples were obtained after 
consent and centrally tested at the All Wales Medical 
Genetics Service and the Department of Cellular 
Pathology, University Hospital of Wales, Cardiff, UK, for 
PIK3CA and PTEN alteration status before random­
isation. If there was an incomplete dataset at the time of 
randomisation, the patient could still be randomly 
assigned using the unobtainable category.
Fulvestrant 500 mg was administered on day 1 of every 
cycle as two intramuscular injections, one into each 
buttock, and an additional loading dose was delivered at 
cycle 1 day 15. Capivasertib 400 mg or matching placebo 
was given orally twice daily on an intermittent weekly 
See Online for appendix
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schedule of 4 days on and 3 days off, starting on cycle 1 
day 15 (to facilitate testing of biomarkers before 
randomisation). Participants continued to receive study 
treatment until disease progression, development of 
unacceptable toxicities, loss to follow­up, or withdrawal of 
consent. Fulvestrant and capivasertib were manu factured 
and provided by AstraZeneca (Cambridge, UK) and 
distributed by Fisher Clinical Services (Horsham, UK).
Participants were reviewed in clinic for toxicities and 
laboratory monitoring on day 1 of every cycle, at the end 
of treatment, and 30 days after treatment. Participants 
who discontinued treatment before progression were 
also monitored monthly. Blood was drawn for analysis of 
sodium, potassium, urea, creatinine, albumin, alanine 
transaminase or aspartate transaminase, alkaline phos­
phatase, bilirubin, calcium and full blood count on day 1 
of every cycle (and day 15 of cycle 1) to cycle 7 and every 
three cycles thereafter. Random blood glucose sampling 
followed the same pattern, but was replaced with fasting 
blood glucose on cycle 1 day 15, cycle 2 day 1, and cycle 3 
day 1. Participants performed home urine dipstick for 
glucose on the third day of capivasertib or placebo dosing 
each week.
Participants completed drug diaries, which were 
returned to the study site at each study visit to aid data 
collection.
The incidence and severity of adverse events and 
serious adverse events were recorded throughout the 
study period with haematological and biochemical 
laboratory tests recorded every 4 weeks. Serious adverse 
events could be reported at any time. Adverse events 
were classified according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events 
version 4.03. Suspected causal associations between 
study drugs and serious adverse events were based on 
investigators’ judgment. Toxicities suspected to be 
related to capivasertib were managed by dose interruption 
or dose reduction to 320 mg, then 240 mg, then 160 mg 
at the same schedule. Repeated dose interruptions and 
continuous interruption of up to 28 days were allowed. 
Participants were to be discontinued following a single 
dose interruption of more than 28 days. Dose reduction 
of fulvestrant to 250 mg was allowed after discussion 
with the chief investigators if an investigator felt that 
unacceptable toxicity could reasonably be attributed to 
fulvestrant or if there were physical difficulties with 
administration of bilateral injections.
CT scans of the chest, abdomen, and, if indicated, 
pelvis were done within 28 days before registration to 
confirm eligibility, and repeated every 8 weeks until 
cycle 7, then every 12 weeks until disease progression. 
Participants who discontinued study drugs for any 
reason other than progression continued to undergo 
imaging assessments until progression. Scans were 
assessed according to RECIST by local radiologists, 
without central review, to determine tumour response 
and date of progression.
Baseline PTEN status was assessed centrally at 
the University Hospital Wales Cellular Pathology 
Department (Cardiff, UK). Freshly cut sections (5 µm 
thick) were taken from each formalin­fixed paraffin­
embedded tumour block. The first section was stained 
with haematoxylin and eosin to identify the area of 
greatest tumour density and tumour percentage, and the 
rest was made available for DNA extraction and whole 
section immunohistochemistry. Immunohistochemistry 
was prepared using DAKO (Ely, UK) PTEN Monoclonal 
Mouse Anti­HumanClone (code M3627), with antigen 
retrieval done with high pH DAKO Target Retrieval 
Solution and the DAKO Autostainer Link 48 automated 
strainer with a pre­detection dilution of 1:100. The 
validation study and full protocol for the PTEN 
immunohistochemistry detection have been published 
previously.18 The PTEN protein expression was docu­
mented using a numeric intensity score of the cyto plasmic 
staining in comparison with the surrounding stroma and 
macrophages (0: null; 1: weak; 2: moderate; and 3: strong).
Figure 1: Trial profile
71 assigned to fulvestrant plus placebo69 assigned to fulvestrant plus capivasertib
183 patients assessed for eligibility at screening
145 consented and registered
38 ineligible
34 did not meet inclusion criteria
2 declined to participate
2 reasons missing 
69 discontinued
67 owing to clinical disease 
progression or death
1 participant choice
1 reason missing
71 included in primary analysis
61 cases of RECIST progression
2 deaths (counted as progression-free 
survival event)
2 deaths (censored)
1 active at data lock (censored)
5 lost to follow-up (censored) 
69 included in primary analysis
47 cases of RECIST progression
2 deaths (counted as progression-free 
survival event)
2 deaths (censored)
7 active at data lock (censored)
11 lost to follow-up (censored) 
60 discontinued
51 owing to clinical disease 
progression or death
8 owing to intolerance to 
treatment due to toxicity and 
serious adverse events 
1 reason missing
5 ineligible
 2 for poor cardiac function
 2 for abnormal liver function
 1 HER2 positive
140 eligible and randomly assigned
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The protocol definition of PTEN loss, for inclusion of a 
patient in the altered pathway subgroup, was either 
immunohistochemistry 0 or weak PTEN staining in less 
than 10% of cancer cells.
Baseline PIK3CA mutational status was assessed 
centrally at the All Wales Genetics Laboratory (Cardiff, 
UK). Paraffin­embedded tissue samples were macro­
dissected and the DNA extracted using the Promega 
(Madison, WI) Maxwell RSC DNA FFPE kit (AS1450). 
Upon arrival of the blood samples (and within 96 h of 
collection), each tube was spun at 2000 g for 10 min at 
4°C. Plasma and buffy coat were separated from the red 
blood cells and spun again to ensure no red blood cells 
remained in the sample. Plasma and buffy coat were 
stored in 1 mL aliquots at –80°C until DNA extraction. 
Cell­free DNA was extracted using the Qiagen (Hilden, 
Germany) QIAamp circulating nucleic acids kit (55114).
The protocol specified that pathway alteration was 
defined as either a hotspot mutation detected by digital 
droplet PCR (ddPCR) on PIK3CA exons 9 or 20 in 
tumour tissue or blood or an immuno histochemistry 
null status for PTEN in tumour tissue (primary tumour 
or metastatic biopsy). The method of mutational analysis 
changed from pyrosequencing to ddPCR during the trial 
(from Nov 9, 2016), which provided greater sensitivity to 
detect mutations. 14 patients who were categorised as 
non­altered on the basis of pyrosequencing analysis had 
insufficient material to carry out a repeat ddPCR analysis. 
Tissue DNA and cell­free DNA were analysed by ddPCR 
using the BioRad (Watford, UK) QX 200 system. Samples 
were analysed for the common PIK3CA exon 9 and 
20 mutations (reference sequence NM_006218.2).
In cases where the PIK3CA alteration status was 
changed by the sequential analysis of plasma and tissue 
and the shift to using ddPCR, the participant was 
analysed according to the final result.
Outcomes
The primary endpoint was investigator­assessed 
progression­free survival, defined as the time from 
randomisation to either the first documented progression 
confirmed by RECIST criteria (regardless of whether the 
patient withdrew from study therapy or received another 
anti­cancer therapy before progression or death from any 
cause). Secondary endpoints were overall survival (defined 
as the time from randomisation to death from any cause), 
objective response (defined as the proportion of 
participants with a complete or partial response, according 
to RECIST version 1.1) and clinical benefit (defined as the 
proportion of participants with an objective response or 
stable disease lasting ≥24 weeks). Analysis of the effect of 
PI3K pathway alteration on these outcomes was planned 
prospectively and subgroup analyses of progression­free 
survival, overall survival, and objective response by PI3K 
pathway alteration were additional secondary outcomes. 
Subgroup analyses of patients with measurable disease 
was also planned to assess progression­free survival, 
Fulvestrant plus capivasertib 
group (n=69)
Fulvestrant plus placebo 
group (n=71)
Median age, years (IQR); range 62 (55–68); 42–81 61 (53–68); 40–82
Eastern Cooperative Oncology Group performance status (physical examination)
0 42 (61%) 49 (69%)
1 25 (36%) 17 (24%)
2 1 (1%) 2 (3%)
Missing 1 (1%) 3 (4%)
Histopathological subtype
Invasive ductal carcinoma 57 (83%) 58 (82%)
Invasive lobular cancer 4 (6%) 12 (17%)
Mixed invasive ductal carcinoma and 
invasive lobular cancer
5 (7%) 0
Other 3 (4%) 1 (1%)
Stage
III inoperable 0 1 (1%)
IV 68 (99%) 68 (96%)
Missing 1 (1%) 2 (3%)
Number of disease sites
Median (IQR); range 2 (2–3); 1–5 2 (1–3); 1–5
1 15 (22%) 19 (27%)
≥2 54 (78%) 52 (73%)
Metastatic sites*
Brain 1 (1%) 1 (1%)
Liver 32 (46%) 29 (41%)
Lung 30 (43%) 28 (39%)
Bone 58 (84%) 55 (77%)
Lymph 28 (41%) 30 (42%)
Pericardial or pleural 5 (7%) 3 (4%)
Chest wall or skin 1 (1%) 3 (4%)
Other visceral 2 (3%) 1 (1%)
Visceral disease 49 (71%) 47 (66%)
Measurable disease† 49 (71%) 50 (70%)
Primary or secondary aromatase inhibitor resistance†
Primary 25 (36%) 26 (37%)
Secondary 44 (64%) 45 (63%)
Aromatase inhibitor given as last treatment 
before registration
57 (83%) 52 (73%)
Bone-only disease 10 (14%) 8 (11%)
Previous breast surgery 59 (86%) 62 (87%)
Previous adjuvant endocrine therapy 60 (87%) 65 (92%)
Any tamoxifen 41 (68%) 43 (66%)
Any aromatase inhibitor 40 (67%) 36 (55%)
Any gonadotropin-releasing hormone 2 (3%) 1 (2%)
Other 1 (2%) 1 (2%)
Missing 0 1 (2%)
Previous adjuvant chemotherapy 36 (52%) 42 (59%)
Anthracycline based 11 (31%) 13 (31%)
Taxane based 5 (14%) 5 (12%)
Anthracycline plus taxane 11 (31%) 9 (21%)
Cyclophosphamide, methotrexate, and 
fluorouracil or capecitabine
7 (19%) 14 (33%)
Other 1 (3%) 1 (2%)
Missing 1 (3%) 0
(Table 1 continues on next page)
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objective response, and dura tion of response in this 
subgroup of patients. Also evaluated were tolerability and 
feasibility of the regimen, as shown by the number of 
participants discontinuing or requiring dose modifi­
cations; fulvestrant pharmac okinetics, specifically whether 
capivasertib affected trough fulvestrant concentrations; 
and safety, defined as the frequency and severity of adverse 
events reported during follow­up.
A more extensive, preplanned, exploratory biomarker 
analysis is currently underway, and when completed, the 
results will be published in a follow­up paper.
Statistical analysis
The hypothesis was that participants treated with 
fulvestrant plus capivasertib would have improved 
median progression­free survival compared with those 
treated with fulvestrant plus placebo. The sample size 
was calculated for a phase 2 screening design, based on a 
primary outcome of progression­free survival, assuming 
a time­to­event hazard ratio of 0·65, 90% power, a one­
sided alpha of 0·20, and an overall loss to follow­up of 
10%.19 Under the assumption that the estimated 
progression­free survival in the control group would be 
5·4 months, a total of 98 events were required in 
138 participants with 18­month accrual and 6­month 
minimum follow­up. If recruitment was restricted to 
participants with PIK3CA mutations, 70 events in 
98 participants would be required to provide 90% power 
to detect a hazard ratio of 0·6 in favour of the combination 
of fulvestrant with capisavertib.
An interim analysis of change in tumour size 8 weeks 
after randomisation in the first 40 participants without 
pathway alteration was planned to allow adaptation of 
recruitment according to participants’ pathway alteration 
status. This approach was designed to look for an early 
futility signal in the non­altered participant group and to 
determine whether the trial should continue only in 
patients with tumours harbouring an altered pathway. 
Details of this analysis are outlined in the study protocol 
(appendix). This analysis showed that activity in the non­
altered group exceeded the prespecified threshold and 
the independent data monitoring committee determined 
that recruitment should remain open to all patients 
regardless of pathway alteration tumour status.
Efficacy analyses for progression­free survival were 
done in the full analysis set, comprising all randomly 
assigned patients, on an intention­to­treat basis. Safety 
analyses included all participants who had received at 
least one dose of study drug. Time to event distri­
butions were estimated with the Kaplan­Meier method. 
Participants with no follow­up RECIST assessment were 
censored at day 1. Participants without disease pro­
gression confirmed by RECIST and those who died or 
progressed after missing the last two RECIST assess­
ments were censored for progression­free survival at the 
date of the last evaluable RECIST assessment or at the 
point of withdrawal of consent. Progression­free survival 
was compared with a one­sided unadjusted log­rank test 
(the primary analysis). Cox regression was used to 
estimate hazard ratios with confidence intervals and 
p values; multivariable Cox regression was used to adjust 
the estimates for the randomisation minimisation 
variables. The proportional hazards assumption was 
checked using Cox­Snell residuals and Schoenfeld’s 
global test. Overall survival was summarised and 
analysed in the same way as progression­free survival; 
participants still alive were censored at the date last seen. 
The proportion of patients with objective response and 
clinical benefit was summarised by trial group and 
analysed using logistic regression.
Two post­hoc analyses were done to calculate the 
progression­free survival of participants allocated to 
Fulvestrant plus capivasertib 
group (n=69)
Fulvestrant plus placebo 
group (n=71)
(Continued from previous page)
Previous endocrine treatment (metastatic or locally advanced setting)
Median lines (IQR); range 1 (1–2); 0–3 1 (1–2); 0–3
0 lines 9 (13%) 6 (8%)
1 line 39 (57%) 45 (63%)
≥2 lines 20 (29%) 20 (28%)
Missing 1 (1%) 0
Metastatic chemotherapy for advanced 
breast cancer
17 (25%) 20 (28%)
Capecitabine based 3 (18%) 6 (30%)
Taxane based 8 (47%) 8 (40%)
Anthracycline based 2 (12%) 6 (30%)
Combined anthracycline and taxane 3 (18%) 0
Other 1 (6%) 0
Pathway altered (subgroup A) 31 (45%) 28 (39%)
Pathway non-altered (subgroup B) 38 (55% 43 (61%)
PIK3CA results—blood
Wild-type 54 (78%) 57 (80%)
Mutation 14 (20%) 13 (18%)
Missing 1 (1%) 1 (1%)
PIK3CA results—tissue
Wild-type 34 (49%) 43 (61%)
Mutation 22 (32%) 19 (27%)
Missing 13 (19%) 9 (13%)
PIK3CA results—blood or tissue†
Wild-type 42 (61%) 47 (66%)
Mutation 27 (39%) 24 (34%)
Missing 0 0
PTEN results†
0 4 (6%) 4 (6%)
1 9 (13%) 8 (11%)
2 13 (19%) 23 (32%)
3 34 (49%) 28 (39%)
Missing 9 (13%) 8 (11%)
Data are n (%), unless otherwise specified. The displayed percentages do include missing values. *Sites are not mutually 
exclusive. †Randomisation minimisation factor.
Table 1: Baseline characteristics
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capivasertib who discontinued or reported a dose 
reduction and the duration of response (defined as the 
time from first documented objective response to the 
first documented progression or death) for participants 
with measurable disease in both the capivasertib and 
placebo groups. A per­protocol sensitivity analysis was 
also done (appendix p 3).
Analyses were done using Stata (version 14.0). Apart 
from the primary outcome, which had a significance 
threshold of 0·2, all p values were considered significant 
at the 0·05 threshold. The independent data monitoring 
committee reviewed accumulating accrual, safety and 
treatment data at regular intervals; however, there were 
no formal stopping guidelines.
This trial is registered with ClinicalTrials.gov, number 
NCT01992952.
Role of the funding source
The funder (AstraZeneca) supplied capivasertib, 
matching placebo, and fulvestrant, contributed to the 
study design, reviewed the draft analysis plan, and 
provided critical review of the draft report, including 
interpretation, but had no role in data collection or data 
analysis. The co­funder (Cancer Research UK) approved 
the study design, but had no role in the drafting of the 
report, or data collection, analysis, or interpretation. The 
sponsor of the study had no role in the writing of the 
report. The corresponding author had full access to all 
the data in the trial and had final responsibility for the 
decision to submit for publication. Additionally, AC and 
CC had full access to the raw data.
Results
Between March 16, 2015, and March 6, 2018, 183 patients 
were screened for eligibility and 140 were randomly 
assigned to receive fulvestrant plus capivasertib (n=69 
[49%]) or fulvestrant plus placebo (n=71 [51%]; figure 1). 
All randomly assigned participants were included in 
primary efficacy and safety analyses. Participants were 
followed up until all had had at least 6 months follow­up 
and the minimum 98 disease progression events required 
for analysis were confirmed. Median progression­free 
survival follow­up was 4·9 months (IQR 1·6–11·6). 
Treatment groups were well balanced for baseline 
characteristics (table 1).
At the time of primary analysis, there had been 
112 progression­free survival events: 49 (71%) in 
69 patients in the capivasertib group compared with 
63 (89%) in 71 in the placebo group. The Schoenfeld’s 
tests were consis tent with the proportional hazards 
assumption, and the assumption was thus adequately 
met (appendix p 2). Median progression­free survival 
was 10·3 months (95% CI 5·0–13·2) in the capivasertib 
group versus 4·8 months (3·1–7·7) in the placebo group, 
giving an unadjusted hazard ratio (HR) of 0·58 (95% CI 
0·39–0·84, 2­sided p=0·0044) and an adjusted HR of 
0·58 (0·39–0·85, 2­sided p=0·0049; figure 2) in favour of 
the capivasertib plus fulvestrant group. The unadjusted 
log­rank test gave a one­sided p value of 0·0018. The trial, 
therefore, met its primary endpoint.
99 (71%) participants had measurable disease (49 in the 
capivasertib group and 50 in the placebo group). Median 
progression­free survival with the combination of 
fulvestrant and capivasertib was significantly longer than 
in the placebo group, both in patients with measurable 
disease (7·6 months [95% CI 4·8–10·5] vs 3·2 months 
[3·1–7·7]) with a HR of 0·61 (95% CI 0·39–0·95, p=0·030) 
and those with non­measurable disease (13·4 months 
[95% CI 7·7–30·1] vs 7·9 months [4·4–10·8]) with a HR of 
0·47 (95% CI 0·22–0·99, 2­sided p=0·046).
20 (29%) of 69 in the capivasertib group achieved an 
objective response compared with six (8%) of 71 in the 
placebo group (odds ratio [OR] 4·42, 95% CI 1·65–11·84, 
2­sided p=0·0031). 38 (55%) of 69 in the capivasertib 
group had clinical benefit versus 29 (41%) of 71 in the 
placebo group (OR 1·78, 95% CI 0·91–3·47, 2­sided 
p=0·093).
20 (41%) of 49 participants with measurable disease in 
the capivasertib group had an objective response compared 
with six (12%) of 50 in the placebo group (OR 5·06, 95% CI 
1·81–14·11, 2­sided p=0·0020). In a post­hoc analysis, the 
median duration of response in patients with measurable 
disease was 7·1 months (95% CI 3·8–9·9) for participants 
in the capivasertib group and 5·0 months (2·7 to not 
reached) for participants in the placebo group (appendix 
p 5).
Assessing the relative efficacy of capivasertib plus 
fulvestrant in participants with PI3K/PTEN pathway 
altered tumours versus those with non­altered tumours 
was a prespecified objective of the trial. A full break­
down of PIK3CA and PTEN alteration status is given in 
the appendix (p 2). There were no cases of weak PTEN 
staining, and all tumours that scored as 0 for immuno­
histochemistry were completely negative for PTEN 
Figure 2: Progression-free survival
HR=hazard ratio.
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staining. These cases are thus termed PTEN null. 
59 (42%) of 140 tumours were designated altered 
(31 [45%] of 69 in the capivasertib group and 28 [39%] of 
71 in the placebo group) and 81 (58%) non­altered 
(38 [55%] of 69 in the capivasertib group and 43 (61%) 
of 71 in the placebo group). The combined result of 
sequential analysis of plasma and tissue and the change 
to ddPCR led to a conversion from non­altered to 
altered status in 21 participants; 12 (17%) of 69 patients 
in the capivasertib group and nine (13%) of 71 patients 
in the placebo group were converted from non­altered 
to altered, and three (4%) in the capivasertib group and 
four (6%) in the placebo group were converted from 
altered to non­altered.
In the PI3K/PTEN pathway non­altered group, median 
progression­free survival was 10·3 months (95% CI 
3·2–13·2) in the capivasertib group and 4·8 months 
(3·0–8·6) in the placebo group. In the altered group, 
median progression­free survival was 9·5 months 
(95% CI 6·6–13·7) in the capivasertib group and 
5·2 months (3·1–8·4) in the placebo group (figure 3). 
The significant improvement in progression­free survival 
seen with fulvestrant and capivasertib versus placebo in 
the overall population was preserved in the non­altered 
group (0·56, 0·33–0·96, p=0·035), but not in patients 
with PI3K/PTEN pathway altered tumours (0·59, 
0·34–1·03, p=0·064). In participants with measurable 
disease, nine (47%) of 19 participants with pathway 
alteration in the capivasertib group had an objective 
response compared with two (11%) of 19 in the placebo 
group (OR 7·65, 95% CI 1·37–42·71, 2­sided p=0·020). 
In patients without pathway alteration, 11 (37%) of 30 in 
the capivasertib group had an objective response 
compared with four (13%) of 31 in the placebo group 
(OR 3·91, 95% CI 1·08–14·14, 2­sided p=0·038).
Overall survival data are immature with a median 
follow­up for survival of 12 months (IQR 6–17). 21 (30%) 
of 69 patients in the capivasertib group and 31 (44%) of 
71 in the placebo group had died at data cutoff. The 
median overall survival was 26·0 months (95% CI 
18·4–32·3) in the capivasertib group and 20·0 months 
(15·1–21·2) in the placebo group with a HR of 0·59 
(95% CI 0·34–1·05, 2­sided p=0·071; figure 4). In the 
non­altered group, median overall survival was 
23·7 months (95% CI 16·8 to not reached) in the 
capivasertib group and 20·3 months (13·3–23·4) in the 
placebo group (HR 0·62, 95% CI 0·30–1·28, 2­sided 
p=0·20). In the altered group, median overall survival 
was 30·5 months (95% CI 17·6 to not reached) in the 
capivasertib group and 18·7 months (95% CI 14·1–21·2) 
in the placebo group (HR 0·53, 95% CI 0·21–1·33, 
2­sided p=0·17).
The median duration of fulvestrant treatment was 
9·2 months (IQR 3·0–14·1) in the capivasertib group 
compared with 4·6 months (2·8–10·5) in the placebo 
group. The median duration of capivasertib treatment 
itself was slightly shorter than that of fulvestrant in the 
combined group at 7·7 months (IQR 1·5–13·5) due to 
discontinuation of capivasertib before disease progression 
in eight (12%) patients. The median duration of placebo 
administration was 4·9 months (IQR 2·3–10·6).
Overall, 28 (41%) of 69 patients in the capivasertib 
group had a capivasertib dose reduction compared with 
one (1%) of 71 in the placebo group; more specifically, 
22 had one, five had two, and one had three capivasertib 
dose reductions. Eight (12%) participants discontinued 
capivasertib because of adverse events—five without 
and three with a previous dose reduction. Of these 
eight participants, rash was reported in six, diarrhoea in 
three, and hypoglycaemia, nausea, vomiting, mouth 
ulcers, and sweating in one each. The most common 
toxicities leading to a dose reduction were rash (14 [20%]), 
diarrhoea (eight [12%]), and nausea or vomiting 
(three [4%]). In a post­hoc exploratory analysis, the 
median progression­free survival in 33 par tici pants 
Figure 3: Progression-free survival in subgroups by PI3K pathway alteration status
(A) The pathway-altered subgroup. (B) The pathway non-altered subgroup. HR=hazard ratio.
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requiring a dose reduction or discon tinuation of 
capivasertib for toxicities was 13·5 months (95% CI 
7·7–21·5), suggesting that dose reduction did not 
compromise treatment efficacy.
The proportion of participants who had grade 3–5 
adverse events (irrespective of causality) was 45 (65%) of 
69 in the capivasertib group and 35 (50%) of 70 in the 
placebo group (table 2; appendix pp 6–18). One patient in 
the placebo group had a grade 5 haemorrhage, attributed 
to disease progression. All cases of severe diarrhoea, 
rash, hyperglycaemia, and vomiting were grade 3, apart 
from one grade 4 diarrhoea in the placebo group. The 
most common grade 3–4 adverse events were hyper­
tension (22 [32%] of 69 in the capivasertib group vs 
17 [24%] of 71 in the placebo group), diarrhoea (ten [14%] 
vs three [4%]), rash (14 [20%] vs 0), infection (four [6%] vs 
two [3%]), and fatigue (one [1%] vs three [4%]). Serious 
adverse reactions (reported only in the capivasertib 
group) were acute kidney injury (two), diarrhoea (three), 
hyperglycaemia (one), loss of consciousness (one), rash 
(two), sepsis (one), and vomiting (one; appendix p 7). 
One death on treatment with capivasertib, from an 
atypical pulmonary infection without disease pro­
gression, was considered possibly treatment related. One 
death in the capivasertib treatment group had an 
unknown cause, and all remaining deaths in both groups 
(19 in the capivasertib group and 31 in the placebo group) 
were disease related.
In the pharmacokinetic analysis, there was no apparent 
difference in trough fulvestrant concentrations between 
participants assigned to capivasertib and those receiving 
placebo (appendix p 19).
Discussion
The results of this study show that the addition of 
capivasertib to fulvestrant therapy significantly improved 
progression­free survival in participants with oestrogen 
receptor­positive HER2­negative breast cancer that had 
progressed on an aromatase inhibitor. The trial met its 
primary objective and, to our knowledge, is the first 
study to show the efficacy of an AKT inhibitor combined 
with fulvestrant in this setting. In the subgroup of 
participants with measurable disease, the addition of 
capivasertib to fulvestrant significantly improved the 
objective response compared with placebo plus 
fulvestrant. However, PI3K pathway alteration status, 
predefined in the protocol as PIK3CA hotspot mutation 
in exons 9 or 20 or PTEN null by immunohistochemistry, 
did not seem to change the effect size of capivasertib, 
although there was not enough statistical power within 
the subgroups to confirm this finding. The overall 
survival data from FAKTION are not yet mature, and no 
statistically significant difference exsists between 
treatment groups. Extended follow­up and a larger phase 
3 study will be required to determine whether the trend 
for improved survival with capivasertib in FAKTION is a 
genuine finding.
The role of the PI3K/AKT/PTEN pathway in driving 
resistance to endocrine therapy is well documented in 
pre­clinical models.5,6 Several clinical trials have tested 
the addition of targeted therapies designed to inhibit 
different proteins in this pathway. The mTORC1 inhi­
bitor everolimus significantly improved progression­free 
survival in combination with exemestane,10 which was 
independent of PIK3CA mutation and PI3K pathway 
alteration status.3 However, this improvement was at the 
expense of an increase in toxicity and overall survival 
was not significantly improved. Two trials have shown 
significant improvements in progression­free survival 
with everolimus versus placebo in combination with 
fulvestrant, although the relative benefits by PI3K 
pathway status are yet to be reported.20,21 The activity of 
the α­specific PI3K inhibitor, alpelisib, in combination 
with fulvestrant was confined to patients whose tumours 
harboured PIK3CA mutations.11 Therefore, the role of 
pathway alter ation in determining drug efficacy could be 
dependent on the specific target and its position in the 
pathway.
The FAKTION data also contrast with the reported 
activity of capivasertib or ipatasertib (another pan­AKT 
inhibitor) in combination with paclitaxel in the PAKT22 
and LOTUS23 studies in metastatic triple­negative breast 
cancer. Both studies reported a significant improvement 
in progression­free survival in the overall population, but 
the benefit was predominantly recorded in tumours 
with activating mutations in PIK3CA or AKT1 or inacti­
vating alterations in PTEN.22,23 However, deficient PTEN 
expression is a more frequent alteration in triple­negative 
breast cancer than in oestrogen receptor­positive, HER2­
negative breast cancer and is associated with increased 
AKT pathway activation,24,25 suggesting that the relative 
benefit of AKT inhibition is context dependent. The 
cross­talk between the oestrogen receptor and AKT 
signalling pathways, which seems to be irrespective 
Figure 4: Overall survival
Censored patients are marked on the curves with a vertical dash. One patient in the placebo group was censored at 
36 months. HR=hazard ratio.
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of mutational status, provides a rational basis for 
effectiveness of the investigational combination beyond a 
mutant population.
The pattern of adverse events observed with capivasertib 
was consistent with other PI3K/AKT pathway inhibitors, 
with diarrhoea, rash, and hyperglycaemia being the most 
Fulvestrant plus capivasertib group (n=69) Fulvestrant plus placebo group (n=71)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Diarrhoea 28 (41%) 18 (26%) 10 (14%) 0 21 (30%) 1 (1%) 2 (3%) 1 (1%)
Rash* 15 (22%) 7 (10%) 14 (20%) 0 11 (15%) 2 (3%) 0 0
Hyperglycaemia 17 (25%) 9 (13%) 3 (4%) 0 10 (14%) 0 0 0
Proteinuria 18 (26%) 8 (12%) 0 0 8 (11%) 0 0 0
Hypertriglyceridaemia 32 (46%) 4 (6%) 1 (1%) 0 18 (25%) 2 (3%) 0 0
Infection (including urinary tract infection) 8 (12%) 14 (20%) 3 (4%) 1 (1%) 5 (7%) 6 (8%) 2 (3%) 0
Vomiting 17 (25%) 8 (12%) 2 (3%) 0 13 (18%) 2 (3%) 0 0
Urea (high) 12 (17%) 1 (1%) 0 0 6 (8%) 0 0 0
Creatinine increased 9 (13%) 2 (3%) 0 0 4 (6%) 0 0 0
Back pain 12 (17%) 5 (7%) 0 0 7 (10%) 3 (4%) 1 (1%) 0
Urinary tract infection 4 (6%) 6 (9%) 1 (1%) 0 2 (3%) 3 (4%) 0 0
ECG QTc prolonged 22 (32%) 2 (3%) 0 0 15 (21%) 4 (6%) 0 0
Cholesterol high 19 (28%) 4 (6%) 0 0 16 (23%) 2 (3%) 0 0
Haemoglobin (low) 14 (20%) 4 (6%) 0 0 7 (10%) 5 (7%) 1 (1%) 0
Hypercalcaemia 16 (23%) 1 (1%) 0 0 12 (17%) 0 0 0
Hypoalbuminaemia 7 (10%) 4 (6%) 0 0 5 (7%) 1 (1%) 0 0
Mucositis oral 7 (10%) 3 (4%) 0 0 5 (7%) 0 0 0
LDL (high) 14 (20%) 0 0 0 10 (14%) 0 0 0
Elevated alanine transaminase 16 (23%) 2 (3%) 0 0 12 (17%) 1 (1%) 2 (3%) 0
Abdominal pain 8 (12%) 2 (3%) 0 0 5 (7%) 1 (1%) 1 (1%) 0
Hypocalcemia 1 (1%) 1 (1%) 0 1 (1%) 0 0 0 0
Nausea 30 (43%) 8 (12%) 0 0 31 (44%) 5 (7%) 0 0
HDL (low) 14 (20%) 0 0 0 12 (17%) 0 0 0
Hyponatraemia 1 (1%) 0 2 (3%) 0 0 0 1 (1%) 0
Hypertension 20 (29%) 21 (30%) 22 (32%) 0 23 (32%) 22 (31%) 17 (24%) 0
Pain (other) 5 (7%) 1 (1%) 2 (3%) 0 5 (7%) 2 (3%) 0 0
Anaemia 2 (3%) 1 (1%) 0 0 0 0 2 (3%) 0
Haemorrhage† 0 0 0 0 0 0 0 0
Cough 5 (7%) 2 (3%) 0 0 5 (7%) 2 (3%) 0 0
Fatigue 24 (35%) 15 (22%) 1 (1%) 0 26 (37%) 12 (17%) 3 (4%) 0
Elevated alkaline phosphatase 15 (22%) 5 (7%) 1 (1%) 0 16 (23%) 4 (6%) 2 (3%) 0
White blood cell count (high) 7 (10%) 3 (4%) 0 0 7 (10%) 4 (6%) 0 0
Pain in extremity 6 (9%) 3 (4%) 0 0 6 (8%) 2 (3%) 2 (3%) 0
Influenza-like symptoms 6 (9%) 2 (3%) 0 0 7 (10%) 2 (3%) 0 0
Neutrophil count decreased 7 (10%) 1 (1%) 0 0 8 (11%) 1 (1%) 0 0
Platelet count decreased 2 (3%) 0 0 1 (1%) 4 (6%) 0 0 0
Hot flashes 8 (12%) 2 (3%) 0 0 12 (17%) 0 0 0
Constipation 6 (9%) 0 0 0 9 (13%) 0 0 0
Injection site reactions 16 (23%) 2 (3%) 1 (1%) 0 21 (30%) 2 (3%) 0 0
Arthralgia 12 (17%) 5 (7%) 2 (3%) 0 17 (24%) 6 (8%) 0 0
Elevated aspartate transaminase 7 (10%) 2 (3%) 0 0 9 (13%) 2 (3%) 2 (3%) 0
Pulse (high) 5 (7%) 0 0 0 9 (13%) 0 0 0
Headache 16 (23%) 1 (1%) 0 0 19 (27%) 4 (6%) 0 0
Dyspnoea 1 (1%) 4 (6%) 0 0 9 (13%) 3 (4%) 1 (1%) 1 (1%)
The table presents toxicities reported in at least 10% of patients in either group or any toxicity reported at grade 3 or worse, irrespective of cause. This table includes 
laboratory value changes that were confirmed as toxicities by research centres. ECG=electrocardiogram. *All preferred terms of rash have been combined. †One patient in the 
treatment group had a grade 5 haemorrhage.
Table 2: Adverse events
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prevalent. More than a third (41%) of participants required 
at least one dose reduction, but only three patients 
subsequently stopped capivasertib because of toxicity. An 
additional five participants (8%) stopped capivasertib 
without previous dose reduction. Although a post­hoc 
exploratory analysis, the median progression­free survival 
in those participants who reduced or discontinued 
capivasertib due to toxicity was not compromised. As 
such, toxicity management guide lines and patient 
education are crucial for future studies in order to manage 
toxicity proactively. Quality of life was not assessed in this 
phase 2 study, but will be key in future studies to assess 
the effect of such management strategies.
The treatment environment is changing for patients 
with oestrogen receptor­positive, HER2­negative meta­
static breast cancer. CDK4/6 inhibitors are now routinely 
used in combination with aromatase inhibitors as first­
line therapy with improvements in overall survival.26,27 
The value of continued CDK4/6 inhibition after pro­
gression is being tested in several clinical trials, but new, 
improved options are clearly needed in this setting. 
Notably, reduction or loss of PTEN has been implicated 
in resistance to both endocrine28 and CDK4/6 inhibitor 
therapy,29 with such cancers responding to AKT 
inhibition but not alpha­specific PI3K inhibition. The 
pre­planned subgroup analysis of the FAKTION study 
showed that the efficacy of AKT inhibition is likely to be 
independent of PI3K pathway alteration. If this 
independence is confirmed, more patients would be 
eligible for capivasertib than alpelisib therapy, which is 
approved only in patients with tumours harbouring 
PIK3CA mutations. Elucidation of biomarkers of activity 
of AKT inhibition in this population remains a research 
priority; however, based on the results of the FAKTION 
trial, capivasertib is an attractive candidate for further 
development in this disease setting.
Analysis of efficacy by pathway alteration was limited 
to hotspot mutation detection in exon 9 and 20 of 
PIK3CA as well as PTEN status by immunohistochemistry. 
When the study was designed, AKT1 mutation was 
reported in only 1–4% of oestrogen receptor­positive 
breast cancers;1,2 thus AKT1 testing was not part of the 
original protocol. AKT1 mutations have been identified 
in 6–7% of oestrogen receptor­positive breast cancer 
metastases,3 and a more comprehensive biomarker 
analysis, including mutational status of all AKT isoforms, 
is underway on FAKTION samples. The full dataset will 
inform future trial design and will help to identify the 
patient population with the greatest potential of benefit 
from capivasertib treatment.
A strength of the study was the randomised nature of 
this phase 2 trial, which means that, although of modest 
size, it provides a rationale for a subsequent phase 3 trial. 
However, the study also has some limitations. First, it 
was a phase 2 screening study, with a relaxed type 1 error 
and one­sided design owing to the interest in detecting 
an active drug. The design does increase the risk of 
obtaining a false­positive result; however, we were willing 
to accept this given that a phase 3 confirmatory trial was 
planned if there was a positive result. Second, no 
adjustment of type 1 error was made for multiple testing 
of secondary and exploratory outcomes, and such 
adjustments should be considered in a confirmatory 
study. Third, the modest size of the study did not allow 
meaningful subgroup analyses, such as for bone­only or 
visceral disease, but these should be evaluated in 
subsequent studies. Fourth, premenopausal women and 
men with advanced breast cancer were excluded. Fifth, 
no FAKTION participants had received previous CDK4/6 
inhibitor therapy, which is now standard of care in 
combination with an aromatase inhibitor or fulvestrant. 
However, clinical30–32 and preclinical data33,34 suggest that 
previous exposure to CDK4/6 inhibition should not 
abrogate the incremental benefit seen with capivasertib. 
Preclinical data suggest that AKT inhibition might be 
superior to PI3K inhibition in this setting,29 but formal 
confirmation of this theory in a randomised trial is 
required.
In conclusion, FAKTION met its primary outcome in 
showing that the combination of fulvestrant and 
capivasertib is tolerable and produces a significant 
improvement in progression­free survival for partici pants 
with advanced oestrogen receptor­positive HER2­negative 
breast cancer who have previously progressed on an 
aromatase inhibitor. These data indicate that capivasertib 
is active in combination with fulvestrant and provide the 
basis for a confirmatory phase 3 study.
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